Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 21:17:2965-2985.
doi: 10.2147/NDT.S304567. eCollection 2021.

Current Perspectives on the Assessment and Management of Gait Disorders in Parkinson's Disease

Affiliations
Review

Current Perspectives on the Assessment and Management of Gait Disorders in Parkinson's Disease

Matthew D Smith et al. Neuropsychiatr Dis Treat. .

Abstract

Gait dysfunction is a key defining feature of Parkinson's disease (PD), and is associated with symptoms of freezing and an increased risk of falls. In this narrative review, we cover the putative mechanisms of gait dysfunction in PD, the assessment of gait abnormalities, and the management of symptoms caused by the inherent difficulty in walking. Our understanding of the causes of gait problems in PD has progressed in recent times, moving from neurocognitive theory to correlates of affected neuronal pathways. In particular, this can be shown to correspond with abnormalities in responses to dual-task paradigms and dysfunction in cholinergic signaling. Great progress has been made in the sophistication and precision of gait assessment; however, it has firmly remained in the research domain. There is significant momentum behind wearable technologies that can be used by patients in their own environment, acting as digital biomarkers that can not only reflect progression but also independently discriminate PD from non-PD individuals. The treatment of gait dysfunction has historically relied on physical therapies and training combined with a view to mitigating the impact of such consequences as falls. Pharmacological therapies that are the mainstay of treatment in PD have tended to address symptoms like bradykinesia; however, optimization of dopaminergic therapies likely has a positive effect on quality of gait. Other targets have been assessed with the goal of improving gait, of which medications that improve cholinergic signaling appear most promising. Neuromodulation techniques are increasingly used in the form of deep-brain stimulation; however, standard targets, such as the globus pallidus interna, have a modest effect on gait. Considerable benefit has been seen through targeting the pedunculopontine nucleus, and a dual-target approach may be warranted. Stimulation of the spinal cord and brain through direct or magnetic approaches has been assessed, but requires further evidence.

Keywords: falls; freezing of gait; gait assessment; neurodegeneration; neuropathology.

PubMed Disclaimer

Conflict of interest statement

EJH is chief investigator for a UK National Institute of Health Research (NIHR) Health Technology Assessment grant, funding a phase III trial of rivastigmine to prevent falls in Parkinson’s disease, and reports a grant from Parkinson’s UK during the conduct of the study, personal fees from Luye outside the submitted work, and personal fees and nonfinancial support from Bial, AbbVie, and Profile outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Schematic of gait dysfunction over disease course.

References

    1. Parkinson’s UK. Incidence and Prevalence of Parkinson’s in the UK: Results from the Clinical Practice Datalink Summary Report. Parkinson’s UK; 2018.
    1. Martinez-Martin P, Skorvanek M, Rojo-Abuin JM, et al. Validation study of the hoehn and yahr scale included in the MDS-UPDRS. Mov Disord. 2018;33(4):651–652. doi:10.1002/mds.27242 - DOI - PubMed
    1. Low V, Ben-Shlomo Y, Coward E, et al. Measuring the burden and mortality of hospitalisation in Parkinson’s disease: a cross-sectional analysis of the English Hospital Episodes Statistics database 2009–2013. Park Relat Disord. 2015;21(5):449–454. doi:10.1016/j.parkreldis.2015.01.017 - DOI - PubMed
    1. Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol. 2002;249(4):419–423. doi:10.1007/s004150200032 - DOI - PubMed
    1. Pouwels S, Bazelier MT, de Boer A, et al. Risk of fracture in patients with Parkinson’s disease. Osteoporos Int. 2013;24(8):2283–2290. doi:10.1007/s00198-013-2300-2 - DOI - PubMed

LinkOut - more resources